Cargando…

Gefitinib versus Docetaxel in Treated Non-small-cell Lung Cancer: A Meta-analysis

The objective of this study was to perform a meta-analysis to evaluate the efficacy and toxicity of gefitinib and docetaxel in treated patients with non-small-cell lung cancer (NSCLC). Methods. A literature search was performed using PubMed and CNKI databases for relevant keywords and the Medical Su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bing, Zuo, Zhanjie, Li, Fang, Yang, Kun, Du, Minjun, Gao, Yushun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter Open 2017
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518716/ https://www.ncbi.nlm.nih.gov/pubmed/28744487 http://dx.doi.org/10.1515/med-2017-0013

Ejemplares similares

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
por: Hong, Junshik, et al.
Publicado: (2010)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Sequence-Dependent Antiproliferative Effects of Gefitinib and Docetaxel on Non-Small Cell Lung Cancer (NSCLC) Cells and the Possible Mechanism
por: Chen, Bei, et al.
Publicado: (2014)

Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma
por: Koukourakis, M I, et al.
Publicado: (1999)

Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ang, et al.
Publicado: (2017)

Long Noncoding RNA H19 Facilitates Small Cell Lung Cancer Tumorigenesis Through miR-140-5p/FGF9 Axis
por: Li, Xingkai, et al.
Publicado: (2020)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

LINC01089 Inhibits Tumorigenesis and Epithelial–Mesenchymal Transition of Non-small Cell Lung Cancer via the miR-27a/SFRP1/Wnt/β-catenin Axis
por: Li, Xingkai, et al.
Publicado: (2020)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

The increased expression and aberrant methylation of SHC1 in non–small cell lung cancer: Integrative analysis of clinical and bioinformatics databases
por: Liang, Yicheng, et al.
Publicado: (2021)

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
por: Kim, Young Saing, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China
por: Gong, Jinhong, et al.
Publicado: (2022)

The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials
por: Wo, Hongmei, et al.
Publicado: (2018)

A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer
por: Zhao, Qingda, et al.
Publicado: (2020)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: Li, Zhe, et al.
Publicado: (2021)

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2019)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2013)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India
por: Mehta, Asmita Anilkumar, et al.
Publicado: (2013)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
por: Ibrahim, Ezzeldin M.
Publicado: (2010)

A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01
por: Atagi, Shinji, et al.
Publicado: (2023)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
por: Bersanelli, Melissa, et al.
Publicado: (2014)

Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
por: Chang, Chia‐Hao, et al.
Publicado: (2017)

Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer
por: Zoli, W, et al.
Publicado: (1999)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis
por: Du, Qingcheng, et al.
Publicado: (2018)

The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis
por: Wailoo, A, et al.
Publicado: (2009)

Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer
por: Jiang, Qi, et al.
Publicado: (2017)

Alkalescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report
por: Bian, Shuang, et al.
Publicado: (2020)

Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
por: Fr Brunsvig, Paal, et al.
Publicado: (2007)

The effect of docetaxel on retinal pigment epithelial cells
por: Li, Jialin, et al.
Publicado: (2022)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer
por: Wang, Hsian-Yu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_glet4ljib7nvrv6l50pdquu4s6